Item 2.02  Results of Operations and Financial Condition.
2seventy bio, Inc. (the "Company") intends to share with investors the amount of
cash, cash equivalents and marketable securities it had on hand as of December
31, 2021 and the revenue received from sales of ABECMA in the U.S. for the year
ended December 31, 2021. Although the Company has not finalized its financial
results for the twelve months ended December 31, 2021, the Company currently
anticipates that its cash, cash equivalents and marketable securities were
approximately $360 million as of December 31, 2021 and that revenue from sales
of ABECMA in the U.S. in 2021 equaled approximately $150 million, which is
shared equally with Bristol-Myers Squibb. This information is unaudited and does
not present all information necessary for an understanding of the Company's
financial condition as of December 31, 2021 and its results of operations for
the twelve months ended December 31, 2021. The Company expects to announce its
full results for the twelve months ended December 31, 2021 on or before March
31, 2022.
Item 7.01  Regulation FD Disclosure.
The Company from time to time presents and distributes to investors slide
presentations to provide updates and summaries of its business. A copy of its
current presentation is being furnished as Exhibit 99.1, which is incorporated
herein by reference.
The information in this Current Report on Form 8-K pursuant to Item 7.01 is
intended to be furnished and shall not be deemed "filed" for purposes of Section
18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise
subject to the liabilities of that section. It may only be incorporated by
reference in another filing under the Exchange Act or the Securities Act of
1933, as amended, if such subsequent filing specifically references the
information furnished pursuant to Item 7.01 of this Current Report.
Item 8.01  Other Events.
On January 11, 2022, the Company issued a press release announcing key milestone
updates and providing other business highlights.
The full text of the press release regarding the announcement is filed as
Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by
reference.
Item 9.01  Financial Statements and Exhibits.
(d) Exhibits
   Exhibit No.                                          Description
      99.1                Slide presentation of 2seventy bio, Inc., furnished herewith
      99.2                Press release issued by 2seventy bio, Inc. on January 11, 2022  .
       104              Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses